Chinese Citric Acid Manufacturers Face Shakeout
This article was originally published in PharmAsia News
Executive Summary
DSM's Wuxi citric acid plant recently stopped production. Industry insiders think the shutdown has little impact on other local citric acid manufacturers and the business due to the company's small share in the China market. However, some express concern that the move indicates weaker demand for the product. Furthermore, stricter environmental standards implemented by the government, coupled with a long-term output surge and recent raw materials price hike, are putting more pressure on the highly polluting industry. Analysts observe that small, low-productivity enterprises which do not meet the environmental protection standards will inevitably be eliminated. To survive the shakeout, the industry looks set for resource consolidation to achieve significance of scale. (Click here for more - Chinese Language)
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.